NVIDIA Partnership And AI Analytics Will Reshape Life Sciences

Published
06 Aug 24
Updated
06 Aug 25
AnalystConsensusTarget's Fair Value
US$213.05
12.7% undervalued intrinsic discount
06 Aug
US$185.91
Loading
1Y
-22.0%
7D
1.1%

Author's Valuation

US$213.1

12.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 7.15%

Shared on30 Apr 25
Fair value Increased 1.26%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on23 Apr 25
Fair value Decreased 0.85%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 7.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 1.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 1.96%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 34%